Chemizon Partners with, Invests in CrownBio | GenomeWeb
NEW YORK (GenomeWeb News) – The drug discovery company Chemizon has struck a strategic partnership with the clinical research company Crown Biosciences to offer a number of drug research capabilities, including proteomics and biomarker services, Chemizon said today.
 
Chemizon, which is a division of Optomagic, also said it has made an investment in CrownBio of an undisclosed amount through a private equity fund. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.